ADMA Biologics ADMA
$13.17 −$0.17 (-1.27%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $13.30 +0.99%
Open$13.26
Prev close$13.34
Day range$13.10 – $13.47
Volume2.45M
Market cap$2.92B
P/E (TTM)17.1
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$141.10M+5.1% YoY
Operating profit$67.76M+32.8% YoY
Net profit$49.88M+36.9% YoY
Diluted EPS$0.22+46.7% YoY
Free cash flow$15.30M+1,523.3% YoY
Operating cash flow$17.37M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin68.5%
Operating margin44.9%
Net margin35.1%
Return on equity41.9%
Return on assets28.0%
Return on invested capital32.4%
Current ratio6.04
Liabilities / assets40.1%
Cash & investments$124.56M
Total debt$201.62M
Net cash (debt)-$77.07M
Free cash flow / sales25.5%
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $141.10M | $124.40M | $114.49M | $510.17M | $139.16M |
| Total Operating Revenue | $141.10M | $124.40M | $114.49M | $510.17M | $139.16M |
| Cost of Revenue | $41.19M | $38.12M | $33.74M | $217.41M | $50.35M |
| Gross Profit | $99.92M | $86.28M | $80.75M | $292.77M | $88.82M |
| Operating Expense | $32.16M | $33.83M | $30.46M | $101.32M | $26.07M |
| Selling and Admin Expenses | $26.56M | $26.74M | $26.74M | $91.58M | $23.51M |
| Research & Development | $4.49M | $6.01M | $2.60M | $4.76M | $1.38M |
| Depreciation & Amortization & Depletion | $60,000.00 | $55,000.00 | $55,000.00 | $144,000.00 | $51,000.00 |
| -Depreciation & Amortization | $60,000.00 | $55,000.00 | $55,000.00 | $144,000.00 | $51,000.00 |
| Other Operating Expenses | $1.06M | $1.03M | $1.06M | $4.84M | $1.13M |
| Operating Profit | $67.76M | $52.45M | $50.29M | $191.44M | $62.75M |
| Net Non-Operating Interest Income (Expense) | -$2.13M | -$2.19M | -$1.01M | -$5.24M | -$1.14M |
| Non-Operating Interest Income | $1.30M | $1.24M | $1.09M | $1.87M | $487,000.00 |
| Non-Operating Interest Expense | $3.43M | $3.42M | $2.10M | $7.11M | $1.63M |
| Other Income (Expense) | -$19,000.00 | -$22,000.00 | $7.84M | -$3.55M | -$17,000.00 |
| Special Income (Charges) | $0.00 | $0.00 | $7.98M | -$3.34M | $0.00 |
| -Gain on Sale Of Business | $0.00 | $0.00 | $7.98M | – | – |
| Other Non-Operating Income (Expenses) | -$19,000.00 | -$22,000.00 | -$140,000.00 | -$212,000.00 | -$17,000.00 |
| Pretax Profit | $65.60M | $50.24M | $57.13M | $182.66M | $61.60M |
| Tax | $15.72M | $12.42M | $11.80M | $35.73M | $12.22M |
| Net Profit | $49.88M | $37.82M | $45.33M | $146.93M | $49.38M |
| Profit from Continuing Operations | $49.88M | $37.82M | $45.33M | $146.93M | $49.38M |
| Net Income to Parent Company | $49.88M | $37.82M | $45.33M | $146.93M | $49.38M |
| Net Income to Common Stockholders | $49.88M | $37.82M | $45.33M | $146.93M | $49.38M |
| Basic EPS | $0.22 | $0.17 | $0.19 | $0.62 | $0.21 |
| Diluted EPS | $0.22 | $0.16 | $0.19 | $0.60 | $0.20 |
| -Less:Other Special Charges | – | – | – | $3.34M | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $732.49M | $684.21M | $665.18M | $624.24M | $624.24M |
| Total Current Assets | $575.86M | $528.20M | $511.17M | $466.51M | $466.51M |
| Cash and Cash Equivalents & Short-Term Investments | $124.56M | $136.02M | $138.15M | $87.63M | $87.63M |
| -Cash and Cash Equivalents | $124.56M | $136.02M | $138.15M | $87.63M | $87.63M |
| Receivables | $169.22M | $138.23M | $135.86M | $158.43M | $158.43M |
| -Accounts Receivable | $169.22M | $138.23M | $135.86M | $158.43M | $158.43M |
| Inventory | $266.12M | $239.31M | $222.10M | $206.47M | $206.47M |
| Other Current Assets | $15.97M | $14.64M | $15.06M | $7.46M | $7.46M |
| Total Non-Current Assets | $156.62M | $156.01M | $154.01M | $157.73M | $157.73M |
| Net PPE | $72.64M | $72.81M | $71.41M | $71.71M | $71.71M |
| -Gross PPE | $116.09M | $114.53M | $111.41M | $110.06M | $110.06M |
| -Accumulated Depreciation | -$43.45M | -$41.72M | -$40.00M | -$38.35M | -$38.35M |
| Goodwill and Other Intangible Assets | $4.11M | $4.11M | $4.16M | $4.16M | $4.16M |
| -Goodwill | $3.53M | $3.53M | $3.53M | $3.53M | $3.53M |
| -Other Intangible Assets | $581,000.00 | $575,000.00 | $630,000.00 | $632,000.00 | $632,000.00 |
| Non-Current Deferred Assets | $70.69M | $69.97M | $69.97M | $73.26M | $73.26M |
| Other Non-Current Assets | $9.18M | $9.13M | $8.47M | $8.60M | $8.60M |
| Total Liabilities | $293.98M | $276.00M | $274.86M | $146.92M | $146.92M |
| Total Current Liabilities | $95.28M | $75.76M | $73.54M | $69.54M | $69.54M |
| Payables | $51.26M | $37.94M | $37.65M | $31.14M | $31.14M |
| -Accounts Payable | $35.66M | $31.72M | $20.52M | $22.52M | $22.52M |
| -Total Tax Payable | $15.60M | $6.22M | $17.12M | $8.62M | $8.62M |
| Current Accrued Expenses | $33.26M | $28.11M | $28.09M | $27.68M | $27.68M |
| Short-Term Debt and Capital Lease Obligation | $5.40M | $4.93M | $4.46M | $3.91M | $3.91M |
| -Current Debt | $4.22M | $3.75M | $3.28M | $2.81M | $2.81M |
| -Current Capital Lease Obligation | $1.18M | $1.18M | $1.18M | $1.10M | $1.10M |
| Other Current Liabilities | $5.36M | $4.78M | $3.35M | $6.82M | $6.82M |
| Total Non-Current Liabilities | $198.70M | $200.25M | $201.32M | $77.38M | $77.38M |
| Long Term Debt and Capital Lease Obligation | $197.41M | $198.91M | $199.95M | $75.98M | $75.98M |
| -Long Term Debt | $191.64M | $192.84M | $193.58M | $69.33M | $69.33M |
| -Long Term Capital Lease Obligation | $5.77M | $6.07M | $6.37M | $6.65M | $6.65M |
| Non-Current Deferred Liabilities | $1.30M | $1.33M | $1.37M | $1.41M | $1.41M |
| Total Equity | $438.51M | $408.21M | $390.33M | $477.32M | $477.32M |
| Stockholders' Equity | $438.51M | $408.21M | $390.33M | $477.32M | $477.32M |
| Capital Stock | $24,000.00 | $24,000.00 | $24,000.00 | $24,000.00 | $24,000.00 |
| -Common Stock | $24,000.00 | $24,000.00 | $24,000.00 | $24,000.00 | $24,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $680.84M | $675.14M | $649.80M | $671.04M | $671.04M |
| Retained Earnings | -$28.62M | -$78.50M | -$116.33M | -$161.65M | -$161.65M |
| Less: Treasury Stock | -$213.74M | -$188.45M | -$143.17M | -$32.09M | -$32.09M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $17.37M | $29.54M | $58.25M | $50.40M | $35.64M |
| Net cash flow from continuing operations | $17.37M | $29.54M | $58.25M | $50.40M | $35.64M |
| Net Income from Continuing Operations | $49.88M | $37.82M | $45.33M | $146.93M | $49.38M |
| Gain/Loss from Continuing Operations | $0.00 | $0.00 | -$7.94M | $3.35M | $9,000.00 |
| Depreciation & Depletion & Amortization | $1.79M | $1.78M | $1.84M | $8.10M | $2.05M |
| Deferred Tax | -$726,000.00 | $3,000.00 | $3.29M | $11.02M | $1.17M |
| Other Non-Cash Items | $170,000.00 | $157,000.00 | $155,000.00 | $574,000.00 | $161,000.00 |
| Change in Working Capital | -$39.95M | -$16.36M | $9.24M | -$139.60M | -$22.52M |
| -Change in Receivables | -$30.99M | -$2.37M | $22.57M | -$108.43M | -$20.76M |
| -Change in Inventory | -$26.80M | -$17.22M | -$15.63M | -$36.23M | -$9.80M |
| -Change in Prepaid Assets | -$1.12M | $19,000.00 | -$1.22M | -$1.25M | -$7,000.00 |
| -Change in Payables and Accrued Expense | $19.27M | $3.50M | $3.87M | $7.54M | $8.44M |
| -Change in Other Current Liabilities | -$304,000.00 | -$290,000.00 | -$340,000.00 | -$1.23M | -$395,000.00 |
| Net cash flow from investing | -$2.07M | -$2.26M | $2.40M | -$21.89M | -$276,000.00 |
| Net Cash Flow from Continuing Investing Activities | -$2.07M | -$2.26M | $2.40M | -$21.89M | -$276,000.00 |
| Net PPE Purchase and Sale | -$2.00M | -$2.26M | -$2.54M | -$22.58M | -$1.08M |
| Net Intangibles Purchase and Sale | -$66,000.00 | $0.00 | -$53,000.00 | -$316,000.00 | -$192,000.00 |
| Net Other Investing Changes | $0.00 | $0.00 | $5.00M | $1.00M | – |
| Financing Cash Flow | -$26.77M | -$29.42M | -$10.13M | -$44.02M | -$9.12M |
| Net Cash Flow from Continuing Financing Activities | -$26.77M | -$29.42M | -$10.13M | -$44.02M | -$9.12M |
| Net Issuance Payments Of Debt | -$937,000.00 | -$469,000.00 | $124.53M | -$938,000.00 | -$469,000.00 |
| Net Common Stock Issuance | -$25.06M | -$25.05M | -$130.19M | -$31.94M | -$8.90M |
| Proceeds from Stock Option Exercised | $10,000.00 | $35,000.00 | $588,000.00 | $2.98M | $430,000.00 |
| Net Other Financing Charges | -$783,000.00 | -$3.93M | -$5.06M | -$14.13M | -$177,000.00 |
| Ending Cash Balance | $124.56M | $136.02M | $138.15M | $87.63M | $87.63M |
| Net Change in Cash | -$11.47M | -$2.13M | $50.52M | -$15.52M | $26.25M |
| Beginning Cash Balance | $136.02M | $138.15M | $87.63M | $103.15M | $61.39M |
| Free Cash Flow | $15.30M | $27.28M | $55.65M | $27.51M | $34.36M |
No comments yet — be the first to weigh in on ADMA.
Sign in to join the discussion.